Modified donor lymphocyte infusion-associated acute graft-versus-host disease after haploidentical T-cell-replete hematopoietic stem cell transplantation: Incidence and risk factors

Clinical Transplantation

Volumn 26, Issue 6, 2012, Pages 868-876

  Yan, Chen Hua ^a   Liu, Dai Hong ^a   Xu, Lan Ping ^a   Liu, Kai Yan ^a   Zhao, Ting ^a   Wang, Yu ^a   Chen, Huan ^a   Chen, Yu Hong ^a   Han, Wei ^a   Huang, Xiao Jun ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Acute graft versus host disease; Allogeneic hematopoietic stem cell transplantation; Donor lymphocyte infusion; Graft versus leukemia; Haploidentical

Indexed keywords

CYCLOSPORIN A; DACLIZUMAB; METHOTREXATE; METHYLPREDNISOLONE;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ARTICLE; CHILD; DONOR LYMPHOCYTE INFUSION; FEMALE; HAPLOIDY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RELAPSE; RISK FACTOR; SCHOOL CHILD; T LYMPHOCYTE; TREATMENT DURATION;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOCYTE TRANSFUSION; LYMPHOCYTES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84870697866     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2012.01618.x     Document Type: Article

References (26)

1. MORTIMER J, BLINDER MA, SCHULMAN S Et Al. Relapse of acute leukemia after marrow transplantation: natural history and results of subsequent therapy. J Clin Oncol 1989: 7: 50.
2. FRASSONI F, BARRETT AJ, GRAÑ ENA A et al. Relapse after allogeneic bone marrow transplantation for acute leukaemia: a survey by the E.B.M.T. of 117 cases. Br J Haematol 1988: 70: 317.
3. KOLB HJ, SCHATTENBERG A, GOLDMAN JM et al. Graft-versus- leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European group for blood and marrow transplantation working party chronic leukemia. Blood 1995: 86: 2041.
4. COLLINS RH Jr, SHPILBERG O, DROBYSKI WR et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997: 15: 433.
5. HUANG XJ, LIU DH, LIU KY et al. Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant 2006: 38: 291.
6. AVERSA F, REISNER Y, MARTELLI MF. Hematopoietic stem cell transplantation from alternative sources in adults with high-risk acute leukemia. Blood Cells Mol Dis 2004: 33: 294.
7. OR R, HADAR E, BITAN M et al. Safety and efficacy of donor lymphocyte infusions following mismatched stem cell transplantation. Biol Blood Marrow Transplant 2006: 12: 1295.
8. HUANG XJ, WANG Y, LIU DH et al. Administration of short-term immunosuppressive agents after DLI reduces the incidence of DLI associated acute GVHD without influencing the GVL effect. Bone Marrow Transplant 2009: 44: 309.
9. HUANG XJ, LIU DH, LIU KY et al. Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation. Haematologica 2007: 92: 414.
10. TOMAS ED, STORB R, CLIFT RA et al. Bone marrow transplantation. N Engl J Med 1975: 292: 895.
11. HUANG XJ, JIANG Q, CHEN H et al. Low-dose methotrexate for the treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2005: 36: 343.
12. COX DR. Regression models and life tables. J R Stat Soc B 1972: 34: 187.
13. HUANG XJ, LIU DH, LIU KY et al. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation. Biol Blood Marrow Transplant 2009: 15: 257.
14. COLLINS RH Jr, GOLDSTEIN S, GIRALT S et al. Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplant 2000: 26: 511.
15. LEVINE JE, BRAUN T, PENZA SL et al. Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stemcell transplantation. J Clin Oncol 2002: 20: 405.
16. SCHATTENBERG A. In relapsed patients after lymphocyte depleted bone marrow transplantation the percentage of donor T lymphocytes correlates well with the outcome of donor leukocyte infusion. Leuk Lymphoma 1999: 32: 317.
17. DAZZI F, SZYDLO RM, CROSS NCP et al. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood 2000: 95: 67.
18. CHALANDON Y, PASSWEG JR, SCHMID C et al. Outcome of patients developing GVHD after DLI given to treat CML relapse: a study by the chronic leukemia working party of the EBMT. Bone Marrow Transplant 2010: 45: 558.
19. VERDONCK LF, PETERSEN EJ, LOKHORST HM et al. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells. Bone Marrow Transplant 1998: 22: 1057.
20. MACKINNON S, PAPADOPOULOS EB, CARABASI MH et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graftversus- leukemia responses from graft-versus-host disease. Blood 1995: 86: 1261.
21. BLOOR AJ, THOMSON K, CHOWDHRY N et al. High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2008: 14: 50.
22. MICHALLET AS, NICOLINI F, FURST S et al. Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT). Bone Marrow Transplant 2005: 35: 601.
23. HUANG XJ, CHANG YJ, ZHAO XY. In vivo induction of Tcell hyporesponsiveness and alteration of immunological cells of bone marrow grafts using granulocyte colony-stimulating factor. Haematologica 2004: 89: 1517.
24. HUANG XJ, CHANG YJ, ZHAO XY. Maintaining hyporesponsiveness and polarization potential of T cells after in vitro mixture of G-CSF mobilized peripheral blood grafts and G-CSF primed bone marrow grafts in different proportions. Transpl Immunol 2007: 17: 193.
25. HUANG XJ, GUO NL, REN HY et al. The comparison of GVL effects between the patients receiving donor peripheral blood stem cells and donor lymphocytes after allogeneic bone marrow transplantation. J Peking Univ (Health Sci) 2003: 35: 103.
26. SCHMID C, LABOPIN M, NAGLER A et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT acute leukemia working party. J Clin Oncol 2007: 25: 4938.